Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications

• DOI: 10.1371/journal.pone.0245767
• Publication Date: 2021-02-12T21:43:30Z
• Authors: Raquel Boff da Costa; Marisa Boff Costa; Larisse Longo; Daniela Elisa Miotto; Gustavo Hirata De...; Matheus Trucollo ...; Mario Reis Álvare...
• Keywords: Dasabuvir; Ombitasvir; Daclatasvir; Ledipasvir; Sofosbuvir; Paritaprevir; Regimen; Hepatitis C; Simeprevir; Ritonavir

Introduction and aim Comorbidities comedication are common in patients with hepatitis C, which could result a risk of drug-drug interaction. The objective this study was to evaluate the prevalence comorbidities, interactions involving direct-acting antivirals population. Methods comedications were evaluated retrospective cohort C patients. Drug-drug estimated real life simulated data on following drug regimens: telaprevir; elbasvir/grazoprevir, ombitasvir/paritaprevir/r/ritonavir (2D regimen), sofosbuvir/simeprevir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir; 2D/dasabuvir (3D regimen); glecaprevir/pibrentasvir sofosbuvir/velpatasvir/voxilaprevir. according University Liverpool database. Statistical analysis performed by SPSS ® 18.0. Results Data from 1433 evaluated. mean patient age 51.7 years (SD ± 10.7), 50.6% female. Direct-acting prescribed for 345 (24.1%) patients, sustained virological response occurred 264 (76.5%). main comorbidities systemic arterial hypertension [436 (30.4%)], diabetes mellitus [352 (24.6%)] depression [130 (9.1%)]. number 1.52 (median [IQR] 1.00 [1.00–2.00]). 3.16 3.00 [1.00–5.00]). A total 12916 found, 1.859 (14.4%) high risk, 1.29 3.13 per patient. 3D regimen, as well sofosbuvir/velpatasvir/voxilaprevir, presented highest interaction indexes. Conclusion interactions. Even when second generation drugs used, occurrence still presents significant risk.